Meeting
2020 ASCO Virtual Scientific Program
Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Children’s Oncology Group (COG) ANBL0032.
Authors
Ami Vijay Desai
University of Chicago Medical Center, Chicago, IL
Ami Vijay Desai , Andrew Gilman , Mehmet Fevzi Ozkaynak , Arlene Naranjo , Wendy B London , Sheena Cretella Tenney , Malcolm Smith , Nita Seibel , Hiroyuki Shimada , Katherine K. Matthay , Susan Lerner Cohn , John M. Maris , Rochelle Bagatell , Paul M. Sondel , Julie R. Park , Alice L. Yu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT00026312
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10523)
DOI
10.1200/JCO.2020.38.15_suppl.10523
Abstract #
10523
Poster Bd #
410
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
The role of autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy: Results of 2 consecutive studies in a single referral institution.
First Author: Jaume Mora
Poster
2022 ASCO Annual Meeting
Patterns of relapse after immunotherapy in patients with high-risk neuroblastoma.
First Author: Scott Moerdler
Poster
2021 ASCO Annual Meeting
Tumor-selective activity of XTX202, a protein-engineered IL-2, in mice without peripheral toxicities in nonhuman primates.
First Author: Jennifer O'Neil
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
The outcome and toxicity profile of checkpoint inhibitor immunotherapy subsequent to high-dose IL-2 in the treatment of metastatic melanoma and renal cell carcinoma.
First Author: Stephanie A. Berg